All In Biotech

Company

Emd Serono

Drugs filed under this Drugs@FDA sponsor name, and trials whose lead sponsor matches it. The same company may file under other names.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

20

13 still marketed

Novel approvals

7

Approvals since 2021

6

Originals and new uses

Phase 3 trials

42

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Pimjetmi approved NovelNov 10, 2026
  • Bavencio new use Oct 11, 2024
  • Tepmetko new use OrphanFeb 15, 2024
  • Bavencio new use OrphanSep 6, 2023
  • Bavencio new use Jul 15, 2022
  • Tepmetko approved NovelAccelerated approvalPriority reviewOrphanFeb 3, 2021
  • Bavencio new use Priority reviewJun 30, 2020
  • Bavencio new use Breakthrough therapyPriority reviewOrphanMay 14, 2019
  • Mavenclad approved Mar 29, 2019
  • Bavencio new use OrphanOct 19, 2018

Drugs in development (0)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline

No investigational drugs in Phase 2 or 3 trials under this sponsor name.

Recruiting Phase 3 trials

Largest first.

Marketed drugs (13)

Newest FDA action first.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.